Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer

Lung Cancer

Volumn 46, Issue 2, 2004, Pages 247-254

  Kaneda, Hiroyasu ^a   Tamura, Kenji ^a   Kurata, Takayasu ^a   Uejima, Hisao ^a   Nakagawa, Kazuhiko ^a   Fukuoka, Masahiro ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

EGFR; epidermal growth factor receptor; IDEAL 1; INTACT 1; Iressa dose evaluated advanced lung cancer 1; National Cancer Institute Common Toxicity Criteria; NCI CTC; non small cell lung cancer; NSCLC; performance status; PS

Indexed keywords

GEFITINIB; STEROID;

ADULT; ADVANCED CANCER; AGE; AGED; ANOREXIA; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DIARRHEA; DRUG RESPONSE; DRUG USE; DRY SKIN; FEMALE; FEVER; FISHER EXACT TEST; GENDER; HEALTH STATUS; HEMATOLOGIC DISEASE; HISTOLOGY; HUMAN; HYPOXEMIA; INTERSTITIAL LUNG DISEASE; LOGISTIC REGRESSION ANALYSIS; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NAUSEA; OBSERVATION; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RASH; RETROSPECTIVE STUDY; REVIEW; SKIN MANIFESTATION; SMOKING; TASK PERFORMANCE; VOMITING;

EID: 4944223891     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.04.032     Document Type: Article

References (34)

1. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest. 111:1997;1710-1717
2. Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311 (1995) 899-909.
3. Shepherd F.A., Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 18:2000;2095-2103
4. Fossella F.V., DeVore R., Kerr R.N., et al. Randomized phase II trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum containing chemotherapy regimens. J Clin Oncol. 18:2000;2354-2362
5. Salomon D., Brandt R., Ciardiello F., et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19:1995;183-232
6. Rusch V., Baselga J., Cordon-Cardo C., et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small-cell lung cancers and adjacent benign lung. Cancer Res. 53:1993;2379-2385
7. Fujino S., Enokibori T., Tezuka N., et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small-cell lung cancer. Eur J Cancer. 32A:1996;2070-2074
8. Pavelic K., Banjac Z., Pavelic J., et al. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res. 13:1993;1133-1137
9. Volm M., Rittgen W., Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer. 77:1998;663-669
10. Baselga J., Pfister D., Cooper M., et al. Phase I study of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 18:2000;904-914
11. Baselga J., Averbuch S. ZD1839 ('Iressa') as an anticancer agent. Drugs. 60(Suppl l):2000;33-40
12. Nakagawa K., Tamura T., Negoro S., et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol. 14:2003;922-930
13. Ranson M., Hammond L., Ferry D., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of phase I trial. J Clin Oncol. 20:2002;2240-2250
14. Herbst R., Maddox A.M., Rothenberg M., et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol. 120:2002;3815-3825
15. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with non-small-cell lung cancer. J Clin Oncol. 21:2003;2237-2246
16. Kris M., Natale R., Herbst R., et al. A phase II trial of ZD 1839 ('Iressa') in advanced non-small-cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimen (IDEAL 2). Proc Am Soc Clin Oncol. 21:2002;292a
17. Giaccone G., Johnson D.H., Manegold C., et al. A phase III clinical trial of ZD 1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT l). Ann Oncol. 113(Suppl 5):2002;A-4
18. Johnson D.H., Herbst R., Giaccone G., et al. ZD1839 ('Iressa') in combination with paclitaxel and carboplatin in chemotherapy naive patients with advanced non-small-cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Ann Oncol. 13(Suppl 5):2002;A-468
19. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 92:2000;205-216
20. Santoro A., Cavina R., Latteri F., et al. Activity of a specific inhibitor, gefitinib (Iressa™, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer. Ann Oncol. 15:2004;33-37
21. Shimomura Y., Matsuo H., Samoto T., Maruo T. Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab. 83:1998;2192-2198
22. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2:2001;127-137
23. Fujiwara K., Kiura K., Ueoka H., et al. Dramatic effect of ZD 1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer. 40:2003;73-76
24. Ranson M., Thatcher N. Commentary on ZD1839 (Iressa) in non small cell lung cancer. Lung Cancer. 40:2003;77-78
25. Cappuzzo F., Ardizzoni A., Soto-Parra H., et al. Epidermal growth factor receptor targeted therapy by ZD1839 (Iressa) in patients with brain metastases from non-small-cell lung cancer (NSCLC). Lung Cancer. 41:2003;227-231
26. Cappuzzo F., Bartolini S., Ceresoli G.L., et al. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). Br J Cancer. 90:2004;82-86
27. Hidalgo M., Siu L.L., Nemunaitis J., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 19:2001;3267-3279
28. Miller V.A., Patel J., Shah N., et al. The epidermal growth factor receptor tyrosine kinase inhibitor Erlotinib (OSI-774) shows promising activity in patients with bronchioalveolar cell carcinoma (BAC): Preliminary results of a phase II trial. Proc Am Soc Clin Oncol. 22:2003;A-2491
29. Wang S.L., Milles M., Wu-Wang C.Y., et al. Effect of cigarette smoking on salivary epidermal growth factor (EGF) and EGF receptor in human buccal mucosa. Toxicology. 75:1992;145-157
30. Cappuzzo F., Gregorc V., Rossi E., et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol. 21:2003;2658-2663
31. Subramaniam S., Whitsett J.A., Hull W., Gairola C.G. Alteration of pulmonary surfactant proteins in rats chronically exposed to cigarette smoke. Toxicol Appl Pharmacol. 140:1996;274-280
32. Foster D.J., Yan X., Bellotto D.J., et al. Expression of epidermal growth factor and surfactant proteins during postnatal and compensatory lung growth. Am J Physiol Lung Cell Mol Physiol. 283:2002;981-990
33. Zhang F., Pao W., Umphress S.M., Jakowlew S.B., et al. Serum levels of surfactant protein D are increased in mice with lung tumors. Cancer Res. 63:2003;5889-5894
34. Tamura K., Yamamoto N., Takeda K., et al. An epidemiological survey for interstitial lung disease induced by gefitinib in patients with advanced non-small-cell lung cancer. West Japan Thoracic Oncology Group (WJTOG). Proc Eur Cancer Soc. 1(Suppl 5):2003;A-56